Evidence map›Paper›PMID 29468554›Full record

ArticleJournal of cardiovascular translational research2018

SDF 1-alpha Attenuates Myocardial Injury Without Altering the Direct Contribution of Circulating Cells.

Andrew B Goldstone, Cassandra E Burnett, Jeffery E Cohen, Michael J Paulsen, Anahita Eskandari, Bryan E Edwards, Arnar B Ingason, Amanda N Steele, Jay B Patel, John W MacArthur and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiovascular translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Chemokines in Myocardial Infarction.Journal of cardiovascular translational research · 2021
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Andrew B GoldstoneDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Cassandra E BurnettDivision of Blood and Marrow Transplantation, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.
Jeffery E CohenDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Michael J PaulsenDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Anahita EskandariDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Bryan E EdwardsDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Arnar B IngasonDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Amanda N SteeleDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Jay B PatelDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
John W MacArthurDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Judith A ShizuruDivision of Blood and Marrow Transplantation, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.
Y Joseph WooDepartment of Cardiothoracic Surgery, School of Medicine, Stanford University, Stanford, CA, USA. joswoo@stanford.edu.
Stanford University · US

Funding

ANGIOGENIC TISSUE ENGINEERING TO LIMIT POST-INFARCTION VENTRICULAR REMODELINGR01HL089315 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI WOO, Y JOSEPH · 2008 to 2023
$6.4M
Vevo LAZR Photoacoustic and Ultrasound Imaging SystemS10OD010344 · OD · STANFORD UNIVERSITY · PI GAMBHIR, SANJIV S · 2013 to 2013
$522k
NHLBI NIH HHS R01 HL089315
6 · The paper itself

Abstract

Stromal cell-derived factor 1-alpha (SDF) is a potent bone marrow chemokine capable of recruiting circulating progenitor populations to injured tissue. SDF has known angiogenic capabilities, but bone marrow-derived cellular contributions to tissue regeneration remain controversial. Bone marrow from DsRed-transgenic donors was transplanted into recipients to lineage-trace circulating cells after myocardial infarction (MI). SDF was delivered post-MI, and hearts were evaluated for recruitment and plasticity of bone marrow-derived populations. SDF treatment improved ventricular function, border zone vessel density, and CD31+ cell frequency post-MI. Bone marrow-derived endothelial cells were observed; these cells arose through both cell fusion and transdifferentiation. Circulating cells also adopted cardiomyocyte fates, but such events were exceedingly rare and almost exclusively resulted from cell fusion. SDF did not significantly alter the proportion of circulating cells that adopted non-hematopoietic fates. Mechanistic insight into the governance of circulating cells is essential to realizing the full potential of cytokine therapies.

Indexed as

AnimalsBone Marrow TransplantationCell DifferentiationCells, CulturedChemokine CXCL12Coronary VesselsDisease Models, AnimalEndothelium, VascularImmunohistochemistryMice, Inbred C57BLMice, TransgenicMyocardial InfarctionMyocytes, CardiacVentricular Function, LeftChemokine CXCL12AngiogenesisBone marrowCell fusionMyocardial infarctionRegeneration

Identifiers

PMID29468554
PMCPMC6103912
OpenAlexW2790485200

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.